Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 6/20 | 0.43 |
| ▸ | TLR2 | O60603 | 2/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | MDM4 | O15151 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15521023 | 1.00 | MDM2 (0.43) | MDM2TLR2HDAC3HDAC6MDM4 | |
| SCHEMBL3431396 | 1.00 | MDM2 (0.43) | MDM2TLR2HDAC3HDAC6MDM4 | |
| SCHEMBL29384293 | 1.00 | MDM2 (0.43) | MDM2TLR2HDAC3HDAC6MDM4 | |
| SCHEMBL29430340 | 1.00 | MDM2 (0.43) | MDM2TLR2HDAC3HDAC6MDM4 | |
| SCHEMBL29358841 | 1.00 | MDM2 (0.43) | MDM2TLR2HDAC3HDAC6MDM4 | |
| SCHEMBL31681344 | 0.98 | MDM2 (0.42) | MDM2TLR2HDAC3HDAC6MDM4 | |
| SCHEMBL31758244 | 0.98 | MDM2 (0.42) | MDM2TLR2HDAC3HDAC6MDM4 | |
| SCHEMBL29528879 | 0.98 | MDM2 (0.42) | MDM2TLR2HDAC3HDAC6MDM4 | |
| SCHEMBL15405716 | 0.98 | MDM2 (0.42) | MDM2TLR2HDAC3HDAC6MDM4 | |
| SCHEMBL30532186 | 0.97 | MDM2 (0.41) | MDM2TLR2HDAC3HDAC6MDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338565-B2 | Macrocyclic compounds for inhibition of tumor necrosis factor alpha | ENSEMBLE THERAPEUTICS CORPORATION (US) | 2012-12-25 | — | — | US | disclosed |
| US-20110033883-A1 | IMAGING DYES AND USE THEREOF | ROYAL COLLEGE OF SURGEONS IRELAND (IE) | 2011-02-10 | — | — | US | disclosed |
| US-20110033883-A1 | IMAGING DYES AND USE THEREOF | ROYAL COLLEGE OF SURGEONS IRELAND (IE) | 2011-02-10 | — | — | US | disclosed |
| US-20100152099-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | ENSEMBLE THERAPEUTICS CORPORATION | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152099-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | TNF, CD40, TNFRSF1A | MDM2 1236/4885TLR2 883/4885HDAC3 1678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.